BioSyent is a publicly traded specialty pharmaceutical company. Our issued and outstanding common shares are listed for trading on the TSX Venture Exchange under the symbol “RX”, and OTC markets (PINK) under the ticker “BIOYF.”

BioSyent named to 2024

TSX Venture Top 50

Why Invest?

Track Record of Profitable Growth
54 Consecutive Profitable Quarters to Q4 2023

Strong Balance Sheet
$28.7 million Cash / $0 Debt at Dec 31, 2023

Well Capitalized
18% Reduction in Share Count from Share Buybacks to December 2023

Quarterly Dividend
Initiated Q4 2022

Experienced and Committed Management Team
>10 years average tenure
~25% management + director ownership

Diversified Portfolio of Innovative Products to Drive
Long-term Growth

10 Approved Products

Scalable Commercial Platform
National Field Salesforce

Market Leading FeraMAX® Pd Platform
#1 Recommended Iron Supplement in Canada for
8 Consecutive Years

YouTube LogoCheck out our previous quarterly webcasts on our YouTube channel.

BioSyent’s Strategy

BioSyent’s strategic focus is on commercializing innovative products with recognizable brand equity sourced through international partnerships.
These products are unique due to manufacturing complexities, novel technologies, therapeutic advantages and, defendable intellectual property rights. The Company works with and supports healthcare practitioners in improving patient lives.

BioSyent’s strategy has three components:

  1. Growth (Revenue and Profit)
  2. Diversification
  3. Corporate Longevity

These three strategic components are prioritized in any investment and capital allocation decisions made by the Company, including any decision to return capital to shareholders.

2022 Annual Report

We made significant investments in growth in 2022 – growth for the current year and, more importantly, growth over the long-term. Our Canadian pharmaceutical brands delivered growth in 2022 as we expanded our field salesforce and made significant marketing investments in our established brands, such as FeraMAX®, as well as our launch brands, Tibella® and Combogesic®.

Read full annual report (PDF)

Information Circular May 2023 (PDF)

BioSyent Annual Report 2022

    Signup now to receive

    Agree with terms

    Investor FAQ

    1. Under what symbol is BioSyent Inc. listed on the stock exchange?
    BioSyent Inc. is listed on the TSX Venture Exchange (TSXV) under the stock symbol RX. Shares of BioSyent are available in the United States on the OTC Pink Marketplace under the trading symbol BIOYF.
    2. Where can I access financial reports and other statutory filings?
    In addition to this website, all historical financial reports and statutory filings can be found at
    3. Looking for general information about your shares?
    All shares issued by our company become the sole responsibility of the shareholder, and all shareholder records are kept by: Computershare Investor Services Inc. 9th Floor 100 University Ave. Toronto, ON M5J 2Y1 Toll free: 1.800.564.6253 | Local Tel: 416.263.9200 | Fax: 416.263.9261
    4. My share certificate says Hedley Technologies Inc. Are they still good? How do I change the name?”
    Any shares of Hedley Technologies Inc. are valid and have already been converted to BioSyent Inc. shares on a 1:1 basis. For more details, please contact: Computershare Investor Services Inc. 9th Floor 100 University Ave. Toronto, ON M5J 2Y1